spacer
home > ebr > spring 2007 > antibody conjugates promise to deliver
PUBLICATIONS
European Biopharmaceutical Review

Antibody Conjugates Promise to Deliver

Shane Olwill, Richard Buick and Christopher Scott at Fusion Antibodies examine emerging strategies for the application of antibody conjugates therapeutics

Antibodies represent the single most exciting drug class currently under clinical development. However, they are also effective agents for site specific delivery of other therapeutic agents within the body. With optimised synthesis and formulation, this approach frequently results in the generation of therapeutically useful levels of drug which have been unattainable at the site of disease through more conventional pharmaceutical delivery approaches. This short review looks at antibody conjugates that are currently in the clinic, and the main strategies being examined for the development of new therapeutic antibody conjugates.

WHY USE ANTIBODY DRUG CONJUGATES?

The application of antibody-based products in the pharmaceutical industry is well established, with over 20 antibody-based products currently marketed for the treatment of conditions including cancer, viral and inflammatory diseases. Sales from this class of therapeutic reached $2 billion in 2000 and are expected to grow to over $25 billion by 2010. It is with little surprise, therefore, that they represent the fastest growing class of drug currently in clinical development.

These biopharmaceuticals elicit their therapeutic effect by docking to a specific binding site or epitope, normally on a targeted protein at the site of disease, leading to a direct or indirect biological response. The selective ability of the antibody to localise to the targeted protein is key to success; large R&D investments across the private and public biotechnology sectors have been dedicated to the identification of suitable unique targets or biomarkers in various disease models. Historically, biomarkers have been examined for the ability of the antibody binding to elicit a desired therapeutic response. For example, trastuzumab (Herceptin) is used in the treatment of early breast cancer where it binds to the cell surface protein HER2/neu, inhibiting proliferation pathways that transduce through this signalling receptor, thus attenuating the growth of the tumour. Alternatively, bevacizumab (Avastin) inhibits the formation of new blood vessels (angiogenesis) in colorectal tumours by sequestering and removing the major proangiogenic factor vascular endothelial growth factor (VEGF) from the tumour micro-environment.

In addition to the active docking of the antibody to its cognate target, it is thought that the antibodies can also elicit their effect on diseased cells by virtue of their constant fragment (Fc)region. There are two possible mechanisms: antibodydependent cellular cytotoxicity (ADCC) and complementdependent cytotoxicity (CDC). In ADCC, the antibody binds to the surface of the diseased cell and the presence and surface density of their Fc regions leads to recruitment of immune effector cells (1). It is thought that trastuzumab is able to increase its effects against HER2/neu breast cancer cells by evoking this response. Alternatively, CDC refers to the recruitment and activation of the complement system by the antibody (2), and is thought to play a role in the therapeutic effect of the anti-CD20 antibody rituximab, used in the treatment of Non-Hodgkin’s lymphoma.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Shane Olwill is the Director of Research and Development at Fusion Antibodies Ltd, a Belfast-based biotechnology company specialising in the development of antibody-based therapeutics in the areas of oncology and angiogenesis. He gained his PhD from the University of Ulster, where he researched alterations in molecular pharmacology as a result of leukemia chemotherapy. Prior to joining Fusion Antibodies, Shane worked in several public and private sector medical laboratories.

Richard Buick is Technical Director of Fusion Antibodies Ltd, prior to which he spent four years at Randox Laboratories as a leader of the molecular biology and protein expression team. Richard has a PhD in Recombinant Antibody Engineering Technologies from the Centre for Cancer Research and Cell Biology, Queen’s University, Belfast, and leads antibody engineering research at Fusion Antibodies.

Christopher Scott is a Lecturer in Biomolecular Science at the School of Pharmacy, Queen’s University, Belfast, UK. He has broad expertise in a wide range of protein expression and capture methodologies, has a PhD in Protease Biochemistry, and was an original member of the founder research team at Fusion Antibodies Ltd. In 2003, Chris joined Queen’s to establish his research team focusing on the development of novel antibodybased therapeutic strategies for the treatment of cancer.

spacer
Shane Olwill
spacer
spacer
spacer
Richard Buick
spacer
spacer
spacer
Christopher Scott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Labguru integrates free video conferencing & documenting tool to support remote lab collaboration during COVID-19

2 April 2020, Cambridge MA – Electronic laboratory notebook (ELN) pioneer, BioData, today announces its support for the global science community with the introduction of a new video conferencing service in its leading Labguru ELN platform, free of charge for all customers.
More info >>

White Papers

Clinical Trial-Specific Travel Programs as a Patient Retention Tool

For many patients, participating in a clinical trial is a major endeavor. Depending on the protocol requirements, study visits can be exhausting. There are a number of reasons why a patient may choose to participate in a trial only to drop out. Conversely, there are several approaches to proactively try to prevent this from happening. There are various methods professionals implement for patient retention. This white paper explores patient travel services as one patient retention strategy.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement